Format

Send to

Choose Destination
Chirality. 2003 May 5;15(4):348-51.

Chiral inversion of the second generation IMiD CC-4047 (ACTIMID ) in human plasma and phosphate-buffered saline.

Author information

1
Celgene Corp., Warren, New Jersey 07059, USA. steo@celgene.com

Abstract

CC-4047 is a racemic second-generation immunomodulatory drug currently in clinical development for various oncologic indications. It has potent effects on key cytokines including tumor necrosis factor-alpha, interleukin (IL-10), and interferon (IFN-gamma). The S-isomer of CC-4047 has been reported to be the more potent enantiomer of the racemate. In this article we report on the rapid racemization of the S-isomer of CC-4047 in human plasma and phosphate-buffered saline. These results support the further development of the racemate instead of the S-isomer.

PMID:
12666243
DOI:
10.1002/chir.10221
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center